Receptor Holdings Adds Alex Casdin to Board of Directors
April 08, 2019 08:50 ET
|
Receptor Holding
SEATTLE, April 08, 2019 (GLOBE NEWSWIRE) -- Alexander W. Casdin, Founder, CEO, and Portfolio Manager of Reneo Capital Management LP, has been named to the Board of Directors of Receptor Holdings...
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
April 01, 2019 07:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
March 21, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it will present...
VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
March 18, 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
March 18, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
The Greater Cannabis Company Announces Uplisting To New Market Tier
February 27, 2019 09:44 ET
|
The Greater Cannabis Company, Inc.
CEO discusses access to institutional investors, increased transparency, and best practice corporate governance Baltimore, MD, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc....
CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
February 27, 2019 07:30 ET
|
CureVac AG
OSLO, Norway, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines,...
New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
February 26, 2019 07:30 ET
|
BeyondSpring, Inc.
BeyondSpring to Present Results at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical...
Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
February 26, 2019 07:00 ET
|
Amicus Therapeutics, Inc.
New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and...
CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference
February 19, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...